Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

MYSTERIOUS: Wave life sciences - You Need To See This

Wave Life Sciences Crashes Deep into Oversold Territory as Obesity Drug Data Disappoints. Should You Buy the Dip?

Wave Life Sciences stock sinks as Phase 1 data for obesity drug disappoints investors. But Oppenheimer still recommends loading up on WVE shares today.

Barchart

Golden Cross Alert: 3 Stocks With Major Upside Potential

Three stocks flashing a golden cross—Sun Communities, Darling Ingredients, and Wave Life Sciences—may offer strong upside potential heading into 2026

MarketBeat

What's Going On With Wave Life Sciences Stock Tuesday?

Wave Life Sciences Ltd. (NASDAQ:WVE) stock rose Tuesday on continued optimism after the company announced data from the lowest therapeutic cohort of the ongoing INLIGHT trial of WVE-007 for weight loss.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Broadcom To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Tuesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Benzinga

Nvidia, AMD, Wave Life Sciences, Toll Brothers And Carvana: Why These 5 Stocks Are On Investors' Radars Today

Major U.S. indexes closed lower on Monday, with the Dow slipping 0.45% to 47,739.32, the SP 500 easing 0.35% to 6,846.51, and the Nasdaq edging down 0.1% to 23,545.90.

Benzinga

Wave Life Sciences One-Shot Obesity Drug Slashes Dangerous Visceral Fat

Wave Life Sciences Ltd. (NASDAQ:WVE) on Monday shared interim data from the lowest therapeutic cohort of the ongoing first-in-human INLIGHT trial evaluating WVE-007, an investigational INHBE GalNAc-siRNA using Wave’s proprietary SpiNA design, for obesity.

Benzinga

Why Is GSK Partner Wave Life Sciences Stock Trading Lower On Wednesday?

Wave Life Sciences Ltd. (NASDAQ:WVE) stock is trading lower on Wednesday after the company shared data from the ongoing Phase 1b/2a RestorAATion-2 Trial of WVE-006 in alpha-1 antitrypsin deficiency.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Bruce Willis’ wife Emma shares sweet family photos as she gives update on dementia research work

‘Our family will continue to keep the faith and never lose hope,’ she wrote on Instagram

The Independent UK

Bruce Willis’s wife shares update after actor’s dementia diagnosis

The ‘Die Hard’ actor’s family announced he had been diagnosed with frontotemporal dementia earlier this year

The Independent UK

Insiders Buy More Than $21M Of 3 Penny Stocks

U.S. stocks traded slightly higher on Wednesday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Benzinga

WAVE Life Sciences's Return On Capital Employed Insights

WAVE Life Sciences (NASDAQ:WVE) brought in sales totaling $1.75 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 8.71%, resulting in a loss of $37.81 million.

Benzinga

Recap: WAVE Life Sciences Q1 Earnings

WAVE Life Sciences (NASDAQ:WVE) reported its Q1 earnings results on Thursday, May 12, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

Benzinga

WAVE Life Sciences Earnings Preview

WAVE Life Sciences (NASDAQ:WVE) is set to give its latest quarterly earnings report on Thursday, 2022-05-12. Here's what investors need to know before the announcement. Analysts estimate that WAVE Life Sciences will report an earnings per share (EPS) of $-0.55.

Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Wave Life Sciences Jump As Low Doses of WVE-004 Lowers Disease Biomarker In Neurological Indications

Wave Life Sciences Ltd's (NASDAQ: WVE)

Benzinga

WAVE Life Sciences's Return On Capital Employed Overview

WAVE Life Sciences (NASDAQ:WVE) brought in sales totaling $1.76 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 458.35%, resulting in a loss of $34.78 million.

Benzinga

WAVE Life Sciences: Q4 Earnings Insights

WAVE Life Sciences (NASDAQ:WVE) reported its Q4 earnings results on Thursday, March 3, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

Benzinga

Earnings Preview: WAVE Life Sciences

WAVE Life Sciences (NASDAQ:WVE) is set to give its latest quarterly earnings report on Thursday, 2022-03-03. Here's what investors need to know before the announcement. Analysts estimate that WAVE Life Sciences will report an earnings per share (EPS) of $-0.51.

Get all your
news in one place.

100's of premium titles.
One news app.

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.